Patents by Inventor Ronald Charles Hawley

Ronald Charles Hawley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
    Publication number: 20240158356
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: April 27, 2023
    Publication date: May 16, 2024
    Applicant: Roche Palo Alto LLC
    Inventors: CHRIS ALLEN BROKA, DAVID SCOTT CARTER, MICHAEL PATRICK DILLON, RONALD CHARLES HAWLEY, ALAM JAHANGIR, CLARA JEOU JEN LIN, DANIEL WARREN PARISH
  • DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
    Publication number: 20230100975
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: March 22, 2022
    Publication date: March 30, 2023
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Substituted pyrazole-pyrimidines, variants thereof, and uses therefore
    Patent number: 11591315
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: February 28, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Crystalline salts and polymorphs of a P2X3 antagonist
    Patent number: 11230533
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: January 25, 2022
    Assignee: AFFERENT PHARMACEUTICALS, INC.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • Pyrimidines and variants thereof, and uses therefor
    Patent number: 11230532
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: January 25, 2022
    Assignee: AFFERENT PHARMACEUTICALS, INC.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE
    Publication number: 20210171505
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 10, 2021
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Substituted pyrazole-pyrimidines, variants thereof, and uses therefore
    Patent number: 10988460
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 27, 2021
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES
    Publication number: 20210008071
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 14, 2021
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen BROKA, David Scott CARTER, Michael Patrick DILLON, Anthony P.D.W. FORD, Ronald Charles HAWLEY, Alam JAHANGIR, Amy Geraldine MOORE, Daniel Warren PARISH
  • DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
    Publication number: 20210009531
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 14, 2021
    Applicant: Roche Palo Alto LLC
    Inventors: CHRIS ALLEN BROKA, DAVID SCOTT CARTER, MICHAEL PATRICK DILLON, RONALD CHARLES HAWLEY, ALAM JAHANGIR, CLARA JEOU JEN LIN, DANIEL WARREN PARISH
  • Pyrimidines and variants thereof, and uses therefor
    Patent number: 10822311
    Abstract: The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: November 3, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • CRYSTALLINE SALTS AND POLYMORPHS OF A P2X3 ANTAGONIST
    Publication number: 20200255386
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE
    Publication number: 20200239451
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: December 11, 2017
    Publication date: July 30, 2020
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR
    Publication number: 20200239421
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: April 13, 2020
    Publication date: July 30, 2020
    Applicant: Afferent Pharmaceuticals Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Crystalline salts and polymorphs of a P2X3 antagonist
    Patent number: 10676444
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: June 9, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • Pyrimidines and variants thereof, and uses therefor
    Patent number: 10662162
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof for example, for the potential treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: May 26, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
    Publication number: 20200115347
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 16, 2020
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR
    Publication number: 20190389811
    Abstract: The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: March 9, 2017
    Publication date: December 26, 2019
    Applicant: Afferent Pharmaceuticals Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • CRYSTALLINE SALTS AND POLYMORPHS OF A P2X3 ANTAGONIST
    Publication number: 20190315698
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Application
    Filed: December 15, 2017
    Publication date: October 17, 2019
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
    Publication number: 20190270713
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R1 and R8 are as defined herein.
    Type: Application
    Filed: May 22, 2019
    Publication date: September 5, 2019
    Applicant: Roche Palo Alto LLC
    Inventors: CHRIS ALLEN BROKA, DAVID SCOTT CARTER, MICHAEL PATRICK DILLON, RONALD CHARLES HAWLEY, ALAM JAHANGIR, CLARA JEOU JEN LIN, DANIEL WARREN PARISH
  • PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR
    Publication number: 20190055202
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof for example, for the potential treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: March 20, 2017
    Publication date: February 21, 2019
    Applicant: Afferent Pharmaceuticals Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever